%20(1000%20x%20500%20%D7%A4%D7%99%D7%A7%D7%A1%D7%9C)%20(2)_edited.jpg)
The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer
Alfandari, A., Moskovich, D., Weisz, A., Katzav, A., Kidron, D., Beiner, M., ... & Ashur‐Fabian, O. (2024). The selenoenzyme type I iodothyronine deiodinase: a new tumor suppressor in ovarian cancer. Molecular Oncology.
Editorial: Crosstalk between thyroid hormones, analogs and ligands of integrin αvβ3 in health and disease. Who is talking now?
Incerpi, S., Ashur-Fabian, O., Davis, P. J., & Pedersen, J. Z. (2023). Crosstalk between thyroid hormones, analogs and ligands of integrin αvβ3 in health and disease. Who is talking now?. Frontiers in Endocrinology, 13, 1119952.
Three-Dimensional Modeling of Thyroid Hormone Metabolites Binding to the Cancer-Relevant αvβ3 Integrin: In-Silico Based Study
Tobi, D., Krashin, E., Davis, P. J., Cody, V., Ellis, M., & Ashur-Fabian, O. (2022). Three-dimensional modeling of thyroid hormone metabolites binding to the cancer-relevant αvβ3 integrin: in-silico based study. Frontiers in Endocrinology, 13, 895240.
Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies
Weisz, A., Abadi, U., Mausbach, L., Gurwitz, D., Ellis, M., & Ashur‐Fabian, O. (2022). Nuclear αvβ3 integrin expression, post translational modifications and regulation in hematological malignancies. Hematological Oncology, 40(1), 73-82.
Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment
Moskovich, D., Finkelshtein, Y., Alfandari, A., Rosemarin, A., Lifschytz, T., Weisz, A., ... & Ashur-Fabian, O. (2021). Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene, 40(44), 6248-6257.
Correction: Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment
Moskovich, D., Finkelshtein, Y., Alfandari, A., Rosemarin, A., Lifschytz, T., Weisz, A., ... & Ashur-Fabian, O. (2021). Targeting the DIO3 enzyme using first-in-class inhibitors effectively suppresses tumor growth: a new paradigm in ovarian cancer treatment. Oncogene, 40(44), 6248-6257.
Corrigendum to "DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer" [Canc. Lett. 501 224-233]
Moskovich, D., Alfandari, A., Finkelshtein, Y., Weisz, A., Katzav, A., Kidron, D., ... & Ashur-Fabian, O. (2021). DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. Cancer letters, 501, 224-233.
Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality
Krashin, E., Silverman, B., Steinberg, D. M., Yekutieli, D., Giveon, S., Fabian, O., ... & Ashur-Fabian, O. (2021). Pre-diagnosis thyroid hormone dysfunction is associated with cancer mortality. Endocrine-Related Cancer, 28(11), 705-713.
αvβ3 Integrin Expression and Mitogenic Effects by Thyroid Hormones in Chronic Lymphocytic Leukemia
Abadi, U., Weisz, A., Kidron, D., Katzav, A., Hercbergs, A., Davis, P. J., ... & Ashur-Fabian, O. (2021). αvβ3 integrin expression and mitogenic effects by thyroid hormones in chronic lymphocytic leukemia. Journal of Clinical Medicine, 10(8), 1766.
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., Abel, S., ... & Bartek, J. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy. autophagy, 17(1), 1-382.
Opposing effects of thyroid hormones on cancer risk: a population-based study
Krashin, E., Silverman, B., Steinberg, D. M., Yekutieli, D., Giveon, S., Fabian, O., ... & Ashur-Fabian, O. (2021). Opposing effects of thyroid hormones on cancer risk: a population-based study. European journal of endocrinology, 184(3), 477-486.
DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer
Moskovich, D., Alfandari, A., Finkelshtein, Y., Weisz, A., Katzav, A., Kidron, D., ... & Ashur-Fabian, O. (2021). DIO3, the thyroid hormone inactivating enzyme, promotes tumorigenesis and metabolic reprogramming in high grade serous ovarian cancer. Cancer letters, 501, 224-233.
Enhanced expression of αVβ3 integrin in villus and extravillous trophoblasts of placenta accreta
Weitzner, O., Seraya-Bareket, C., Biron-Shental, T., Fishamn, A., Yagur, Y., Tzadikevitch-Geffen, K., ... & Ashur-Fabian, O. (2021). Enhanced expression of αVβ3 integrin in villus and extravillous trophoblasts of placenta accreta. Archives of Gynecology and Obstetrics, 303, 1175-1183.
The identification of nuclear αvβ3 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions
Seraya-Bareket, C., Weisz, A., Shinderman-Maman, E., Teper-Roth, S., Stamler, D., Arbib, N., ... & Ashur-Fabian, O. (2020). The identification of nuclear αvβ3 integrin in ovarian cancer: non-paradigmal localization with cancer promoting actions. Oncogenesis, 9(7), 69.